Renal cell carcinoma.
Renal cell carcinoma remains a devastating disease known for insidious onset, with patients often having advanced incurable disease at the time of diagnosis. Biologic therapy with IL-2 offers a chance for prolonged remission for a minority of patients, but its toxicities preclude most patients from ever receiving it. Preclinical experiments and early results of novel clinical trials based on the latest theories in molecular oncology and immunology are leading to promising new treatments for this disease.